URGN · Urogen Pharma Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50.96M | - | $27.48M | $24.21M | $20.25M | - | $25.20M | $21.85M | $18.78M | - |
| Cost of Revenue | $4.14M | - | $3.28M | $3.55M | $2.33M | - | $2.45M | $2.23M | $1.73M | - |
| Gross Profit | $46.82M | - | $24.20M | $20.66M | $17.92M | - | $22.75M | $19.62M | $17.05M | - |
| R&D | $15.60M | - | $14.01M | $18.91M | $19.87M | - | $11.36M | $15.40M | $15.49M | - |
| SG&A | $51.49M | - | $37.58M | $43.20M | $34.97M | - | $28.94M | $30.06M | $27.30M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $75.0K | - | $100.0K | $100.0K | $72.0K | - | $100.0K | $100.0K | $123.0K | - |
| Operating Income | ($20.26M) | - | ($27.39M) | ($41.45M) | ($36.91M) | - | ($17.55M) | ($25.84M) | ($25.74M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($4.77M) | - | ($1.05M) | $1.01M | $392.0K | - | $91.0K | $38.0K | $54.0K | - |
| Net Income | ($23.57M) | - | ($33.35M) | ($49.94M) | ($43.84M) | - | ($23.67M) | ($33.40M) | ($32.29M) | - |
| EPS - Basic | ($0.47) | - | ($0.69) | ($1.05) | ($0.92) | - | ($0.55) | ($0.91) | ($0.97) | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $109.97M | $110.75M | $90.04M | $92.90M | $104.03M | $171.99M | $124.92M | $219.97M | $131.44M | $95.00M |
| Accounts Receivable | $55.41M | $33.08M | $19.70M | $19.65M | $19.64M | $20.30M | $22.80M | $17.41M | $14.16M | $15.44M |
| Inventory | $20.92M | $16.46M | $8.34M | $7.13M | $7.59M | $9.23M | $7.59M | $7.44M | $7.24M | $5.67M |
| Accounts Payable | $17.21M | $12.14M | $10.28M | $13.56M | $14.57M | $10.93M | $5.56M | $8.32M | $6.26M | $6.51M |
| Current Assets | $237.46M | $186.02M | $168.55M | $196.87M | $237.18M | $276.13M | $295.10M | $278.97M | $196.76M | $169.19M |
| Total Assets | $253.69M | $200.46M | $185.05M | $208.72M | $247.62M | $285.71M | $301.94M | $281.85M | $200.57M | $178.31M |
| Current Liabilities | $50.63M | $46.42M | $42.24M | $47.55M | $42.00M | $45.95M | $32.79M | $34.22M | $26.34M | $31.21M |
| Long-term Debt | $189.53M | $122.21M | $122.11M | $122.51M | $122.11M | $121.73M | $121.71M | $97.81M | $97.59M | $98.55M |
| Total Liabilities | $377.94M | $305.93M | $300.45M | $302.09M | $294.08M | $294.51M | $276.43M | $251.53M | $240.71M | $243.52M |
| Stockholders' Equity | ($124.25M) | ($105.47M) | ($115.41M) | ($93.38M) | ($46.46M) | ($8.80M) | $25.52M | $30.31M | ($40.13M) | ($65.21M) |
| Retained Earnings | ($983.29M) | ($959.72M) | ($933.35M) | ($900.00M) | ($850.07M) | ($806.22M) | ($768.71M) | ($745.04M) | ($711.63M) | ($679.35M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($45.32M) | - | - | - | ($42.02M) | - | - | - | ($31.73M) | - |
| Investing Cash Flow | ($20.69M) | - | - | - | ($25.96M) | - | - | - | $13.52M | - |
| Financing Cash Flow | $65.20M | - | - | - | $34.0K | - | - | - | $54.66M | - |
| CapEx | $54.0K | - | - | - | $44.0K | - | - | - | $0 | - |
| Free Cash Flow | ($45.37M) | - | - | - | ($42.07M) | - | - | - | ($31.73M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 91.9% | - | 88.1% | 85.3% | 88.5% | - | 90.3% | 89.8% | 90.8% | - |
| Operating margin | -39.8% | - | -99.7% | -171.2% | -182.3% | - | -69.6% | -118.3% | -137.1% | - |
| EBITDA margin | -39.6% | - | -99.3% | -170.8% | -181.9% | - | -69.2% | -117.8% | -136.4% | - |
| Net margin | -46.3% | - | -121.3% | -206.2% | -216.5% | - | -93.9% | -152.9% | -171.9% | - |
| Free cash flow margin | -89.0% | - | - | - | -207.7% | - | - | - | -169.0% | - |
| FCF / Net income | 1.92 | - | - | - | 0.96 | - | - | - | 0.98 | - |
| R&D / Revenue | 30.6% | - | 51.0% | 78.1% | 98.1% | - | 45.1% | 70.5% | 82.5% | - |
| SG&A / Revenue | 101.0% | - | 136.8% | 178.4% | 172.6% | - | 114.8% | 137.6% | 145.4% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.3% | - | -18.0% | -23.9% | -17.7% | - | -7.8% | -11.9% | -16.1% | - |
| Return on equity | 19.0% | - | 28.9% | 53.5% | 94.4% | - | -92.8% | -110.2% | 80.4% | - |
| Return on invested capital | -24.5% | - | -322.8% | -112.4% | -38.5% | - | -9.4% | -15.9% | -35.4% | - |
| Liquidity | ||||||||||
| Current ratio | 4.69 | 4.01 | 3.99 | 4.14 | 5.65 | 6.01 | 9.00 | 8.15 | 7.47 | 5.42 |
| Quick ratio | 4.28 | 3.65 | 3.79 | 3.99 | 5.47 | 5.81 | 8.77 | 7.93 | 7.20 | 5.24 |
| Cash ratio | 2.17 | 2.39 | 2.13 | 1.95 | 2.48 | 3.74 | 3.81 | 6.43 | 4.99 | 3.04 |
| Leverage | ||||||||||
| Debt / Equity | -1.53 | -1.16 | -1.06 | -1.31 | -2.63 | -13.83 | 4.77 | 3.23 | -2.43 | -1.51 |
| Debt / Assets | 0.75 | 0.61 | 0.66 | 0.59 | 0.49 | 0.43 | 0.40 | 0.35 | 0.49 | 0.55 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -2.04 | -1.90 | -1.60 | -2.24 | -5.33 | -32.46 | 11.83 | 9.30 | -5.00 | -2.73 |
| Liabilities / Assets | 1.49 | 1.53 | 1.62 | 1.45 | 1.19 | 1.03 | 0.92 | 0.89 | 1.20 | 1.37 |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | - | 0.15 | 0.12 | 0.08 | - | 0.08 | 0.08 | 0.09 | - |
| Inventory turnover | 0.20 | - | 0.39 | 0.50 | 0.31 | - | 0.32 | 0.30 | 0.24 | - |
| Days sales outstanding | 397d | - | 262d | 296d | 354d | - | 330d | 291d | 275d | - |
| Days inventory outstanding | 1845d | - | 929d | 733d | 1189d | - | 1130d | 1219d | 1530d | - |
| Days payable outstanding | 1518d | - | 1145d | 1395d | 2282d | - | 827d | 1362d | 1322d | - |
| Cash conversion cycle | 724d | - | 46d | -366d | -739d | - | 633d | 148d | 483d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 151.6% | - | 9.0% | 10.8% | 7.8% | - | 20.9% | 3.4% | 9.2% | - |
| Revenue CAGR (3y) | 43.6% | - | 19.5% | 13.4% | 14.3% | - | 30.5% | 18.8% | 35.9% | - |
| Revenue CAGR (5y) | 46.8% | - | 51.3% | 130.5% | - | - | 145.4% | 313.8% | 108.1% | - |
| Gross profit growth (YoY) | 161.2% | - | 6.4% | 5.3% | 5.1% | - | 23.1% | 4.9% | 14.2% | - |
| Operating income growth (YoY) | 45.1% | - | -56.1% | -60.4% | -43.4% | - | -30.0% | -68.0% | -16.8% | - |
| Net income growth (YoY) | 46.2% | - | -40.9% | -49.5% | -35.8% | - | -8.2% | -38.4% | -6.9% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -7.8% | - | - | - | -32.6% | - | - | - | -22.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -167.5% | -1098.2% | - | - | -15.8% | 86.5% | - | - | 65.6% | 27.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$109.79M totalJelmyto$93.99M · 85.6%
Zusduri$15.80M · 14.4%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing UroGen Pharma Ltd. against the 5 most active filers in the same SIC group.